CN111848537A - Synthesis method of chlorogenic acid derivative and antibacterial activity determination method - Google Patents

Synthesis method of chlorogenic acid derivative and antibacterial activity determination method Download PDF

Info

Publication number
CN111848537A
CN111848537A CN202010798623.3A CN202010798623A CN111848537A CN 111848537 A CN111848537 A CN 111848537A CN 202010798623 A CN202010798623 A CN 202010798623A CN 111848537 A CN111848537 A CN 111848537A
Authority
CN
China
Prior art keywords
chlorogenic acid
compound
dichloromethane
reaction
acid derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010798623.3A
Other languages
Chinese (zh)
Other versions
CN111848537B (en
Inventor
熊伟
韩晓丹
吴磊
李雄辉
胡居吾
付建平
王慧宾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Applied Chemistry Jiangxi Academy of Sciences
Original Assignee
Institute of Applied Chemistry Jiangxi Academy of Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Applied Chemistry Jiangxi Academy of Sciences filed Critical Institute of Applied Chemistry Jiangxi Academy of Sciences
Priority to CN202010798623.3A priority Critical patent/CN111848537B/en
Publication of CN111848537A publication Critical patent/CN111848537A/en
Application granted granted Critical
Publication of CN111848537B publication Critical patent/CN111848537B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a method for synthesizing chlorogenic acid derivatives, which comprises the following steps: step 1, protecting alcoholic hydroxyl groups of chlorogenic acid; step 2, protecting phenolic hydroxyl groups of chlorogenic acid; step 3, synthesizing chlorogenic acid derivatives containing oxazole or pyrazole rings; step 4, removing a hydroxyl protecting group; the chlorogenic acid high-efficiency antibacterial agent can be prepared, has a remarkable antibacterial effect, and can enhance the stability of unsaturated double bonds and improve the in-vivo biological activity of chlorogenic acid.

Description

Synthesis method of chlorogenic acid derivative and antibacterial activity determination method
Technical Field
The invention relates to the technical field of chlorogenic acid, in particular to a synthetic method of a chlorogenic acid derivative and an antibacterial activity determination method.
Background
Chlorogenic acid (Chlorogenic acid) is depside formed by the condensation of caffeic acid (caffeic acid) and quinic acid (quinic acid, 1-hydroxyhexahydrogallic acid), namely 3-O-caffeoylquinic acid (3-O-caffeoylquinic acid), and is a phenylpropanoid compound generated by plants through the shikimic acid pathway in the aerobic respiration process. Chlorogenic acid is a main effective component of a plurality of medicinal materials, such as honeysuckle, oriental wormwood, eucommia bark and the like, and Chinese patent medicines, such as Fuganni, honeysuckle injection, acne oral liquid and the like, for resisting bacteria, removing toxicity, diminishing inflammation and benefiting gallbladder, and is also an important index for quality control of certain traditional Chinese medicine preparations. Chlorogenic acid has wide bioactivity, and has antibacterial, antiviral, leukocyte increasing, liver protecting, gallbladder function promoting, antitumor, blood pressure lowering, blood lipid reducing, free radical scavenging, and central nervous system exciting effects. The research on the biological activity of chlorogenic acid by modern science is deeply carried out in a plurality of fields of food, health care, medicine, daily chemical industry and the like.
Due to the existence of ester bonds, unsaturated double bonds and three unstable groups of dihydric phenol in the molecular structure of the chlorogenic acid, the in vivo bioactivity of the chlorogenic acid is reduced to a great extent. There have been considerable literature and experimental data for many years on chemical modification or modification of chlorogenic acids around their unfavorable physicochemical and biological properties, wherein simple modification based on the chlorogenic acid skeleton is an effective way to obtain highly active chlorogenic acid derivatives, and most of the modifications are focused on multiple hydroxyl substituents, carboxyl groups and ester groups in the molecular structure of chlorogenic acids according to their modification sites (chinese herbal medicine, 2020, 51(4),937), while modifications of unsaturated carbon-carbon double bonds are rare.
Most of the compounds containing oxazole and pyrazole structures have wide biological activity, have obvious curative effect on resisting fungi, bacteria and malignant tumors, and are used as important medical intermediates and lead compounds. For example, muscial is a compound containing an oxazoline ring skeleton, and has been confirmed to have natural anticancer, antibacterial and tranquilizing functions (eur.j.med.chem.1995,30,839); in 2003, Barbachyn and the like design and synthesize a series of compounds containing oxazoline parent nucleus, and activity screening finds that partial substances have better antibacterial activity and good pharmacokinetic properties than linezolid (J.Med.chem.2003,46,284); the 5-phosphoryl-3-aryl isoxazoline reported by Zhang Chang water and the like in 2012 has certain inhibitory activity on neuraminidase (Chin.J.org.chem.2012,32,1336); in 2013, the compound containing oxazole ring synthesized by Wangshi et al shows strong inhibition effect on escherichia coli and bacillus subtilis (Chin.J.org.chem.2013,33,2196); since the 70's of the 20 th century, Ankhiwala M.D. et al reported that certain substituted pyrazoline compounds have excellent fungicidal activity (Journal of the Indian Chemical Society, 1990, 67(6), 514); subsequently, antibacterial activity of pyrazoline derivatives was successively reported by Turan-Zitounia G and Ponjin (Archiv Der Pharmazie, 2005, 338, 96; proceedings of the national university of Yunnan (Nature edition), 2007, 16(1), 33); in 2020, serial pyrazoline derivatives are combined by the cinnabar subject, the bacteriostatic effects of the series pyrazoline derivatives on gram-positive bacteria, gram-negative bacteria and fungi are analyzed, and the pyrazoline compounds are found to have different degrees of inhibitory action on various bacteria (industrial catalysis, 2020, 28(2) and 53).
Disclosure of Invention
In order to solve the above problems, the present invention aims to provide a method for synthesizing chlorogenic acid derivatives, and also discloses a method for measuring antibacterial activity of chlorogenic acid derivatives prepared by the above synthesis method.
In order to achieve the purpose, the invention adopts the following technical scheme:
a method for synthesizing chlorogenic acid derivatives comprises the following steps:
step 1, protecting alcoholic hydroxyl groups of chlorogenic acid: dissolving chlorogenic acid in acetone, adding p-toluenesulfonic acid into a reaction system, and stirring at room temperature for 3-5 hours; TLC monitoring reaction progress until reactant chlorogenic acid disappears; after the reaction is finished, adding an alkaline substance, neutralizing the residual p-toluenesulfonic acid until the pH value is 6-7.5, performing suction filtration, and concentrating the filtrate to obtain a compound A;
step 2, protecting phenolic hydroxyl of chlorogenic acid: adding the compound A obtained in the step 1, acetic anhydride with a phenolic hydroxyl protecting group and a catalyst 4-Dimethylaminopyridine (DMAP) into a solvent Dimethylformamide (DMF), and stirring at room temperature for reaction for 2-3 h; monitoring the reaction, adding saturated saline solution into the reaction system for washing, then extracting by using an extracting agent, combining organic phases, purifying the organic phases by using silica gel chromatography, and separating out a compound B by using dichloromethane and methanol as eluent;
and 3, synthesizing chlorogenic acid derivatives containing oxazole or pyrazole rings: dissolving the compound B obtained in the step 2 in an organic solvent, adding 1, 3-dipole C, a catalyst copper salt and an oxidant into a reaction system, and reacting at the temperature of 50-70 ℃ for 5-8 h; TLC monitoring reaction progress until compound B disappears completely, stopping reaction, adding saturated salt solution into reaction system, washing, extracting with extractant, combining organic phase, purifying organic phase with silica gel chromatography, eluting with dichloromethane and methanol to separate out compound D;
the 1, 3-dipole C is of the formula (I)
Figure BDA0002626550680000031
Wherein R is H, Bn, Me, Ph, 4-MePh, 4-MeOPh, 4-ClPh or CH2CH2CO; ar is Ph, 4-MePh, 4-MeOPh, 4-ClPh, 2-MePh or 2-ClPh; x is O or N;
and 4, removing a hydroxyl protecting group: adding the compound D obtained in the step 3 into a mixture of trifluoroacetic acid and dichloromethane, reacting at room temperature for 1.5-3 h, monitoring the reaction process by TLC, after the reaction is finished, adding saturated salt solution into a reaction system for washing, extracting with an extracting agent, combining organic phases, purifying the organic phases by silica gel chromatography, and taking dichloromethane and methanol as eluents to obtain a final product E, namely a chlorogenic acid derivative, wherein the yield is 70-85%;
the synthetic route is as follows:
Figure BDA0002626550680000041
further, in the step 1, the dosage ratio of chlorogenic acid to acetone is 10 mmol: 20-30 mL, wherein the molar ratio of chlorogenic acid to p-toluenesulfonic acid is 1: 1.0-1.2, and the alkaline substance is saturated sodium carbonate or saturated sodium bicarbonate.
Further, in the step 2, the molar ratio of the compound A, acetic anhydride and 4-dimethylaminopyridine is 1: 1.5-2.0: 1-1.5, wherein the dosage ratio of the compound A to the dimethylformamide is 10 mmol: 25-35 mL, wherein the volume ratio of dichloromethane to methanol is 30: 1 to 3.
Further, in the step 3, the ratio of the compound B to the organic solvent is 10 mmol: 20-30 mL, wherein the molar ratio of the compound B to the 1, 3-dipole C to the catalyst copper salt to the oxidant is 1: 1.0-1.2: 0.1-0.2: 0.2-0.5, wherein the volume ratio of dichloromethane to methanol is 10: 1 to 2.
Further, in the step 3, the copper salt of the catalyst is cupric chloride, cupric bromide, cupric acetate, cuprous acetate, cupric trifluoroacetate or cupric trifluoromethanesulfonate.
Further, in the step 3, the oxidant is tert-butyl peroxy-alcohol (TBHP), m-chloroperoxybenzoic acid (m-CPBA), N-bromosuccinimide (NBS), 2,6, 6-tetramethylpiperidinyloxyammonium tetrafluoroborate (T)+BF4) Or iodobenzene acetate PhI (OAc)2。
Further, in the step 3, the organic solvent is DMF, DMA, DMSO, 1,4-dioxane, 1,2-dichloroethane, CH3CN or THF.
Further, in the above step 4, the molar ratio of the compound D, trifluoroacetic acid and dichloromethane is 1: 2-3: 1, the volume ratio of dichloromethane to methanol is 20: 1 to 2.
Further, the extractant used in the above steps 2,3 and 4 is dichloromethane, ethyl acetate, n-butanol or chloroform.
The structural formula of the chlorogenic acid derivative prepared by the method is shown as the formula (II):
Figure BDA0002626550680000051
wherein R is H, Bn, Me, Ph, 4-MePh, 4-MeOPh, 4-ClPh or CH2CH2CO; ar is Ph, 4-MePh, 4-MeOPh, 4-ClPh, 2-MePh or 2-ClPh; x is O or N.
The method for measuring the antibacterial activity of the chlorogenic acid derivative comprises the following steps: dissolving chlorogenic acid derivatives with acetonitrile as solvent, and preparing into stock solutions with mass percentage concentrations of 20%, 40%, 60%, 80%, and 100%, respectively; dipping with sterile cotton swab at 1.0 × 103～2.0×103cfu·mL-1The bacterial liquid is uniformly coated on the surface of a culture medium plate and is pasted firmly, and the used strain of the bacterial liquid is escherichia coli, staphylococcus aureus or candida albicans; taking out the filter paper sheets soaked by the stock solutions with different concentrations by using sterile forceps, and spreading the filter paper sheets on the surfaces of different culture media; putting the culture medium coated with the bacterial liquid into a culture dish, inverting the culture dish, putting the culture dish into a thermostat with the temperature of 35-37 ℃ for culturing for 20-24 hours, and observing the phenomenon; transparent circular rings-bacteriostatic rings with different sizes appear on the culture medium respectively, and the bacteriostatic activity of the chlorogenic acid derivative can be obtained by measuring the diameters of the bacteriostatic rings.
The invention also protects the application of the chlorogenic acid derivative in preparing antibacterial drugs.
Due to the adoption of the technical scheme, the invention has the following advantages:
according to the synthesis method of the chlorogenic acid derivative, an oxazole or pyrazole structure with antibacterial activity is introduced into the chlorogenic acid derivative through cycloaddition reaction of an unstable group carbon-carbon double bond in the chlorogenic acid structure and a1, 3-dipole according to an activity superposition principle to prepare the chlorogenic acid efficient antibacterial agent, so that the stability of unsaturated double bonds can be enhanced, and the in-vivo biological activity of the chlorogenic acid can be improved; the synthesis route is simple and efficient, the raw material source is wide, the cost is low, the operation is easy, and the yield is high.
The chlorogenic acid derivative prepared by the method has the advantages of novel structure, obvious antibacterial effect and high yield, and is suitable for industrial production.
Detailed Description
The present invention will be further described in detail with reference to the following examples; however, the following examples are merely illustrative, and the present invention is not limited to these examples.
Example 1
A method for synthesizing chlorogenic acid derivatives comprises the following steps:
Figure BDA0002626550680000061
step 1, protecting alcoholic hydroxyl groups of chlorogenic acid: dissolving 10mmol of chlorogenic acid in 25mL of acetone, adding 10mmol of p-toluenesulfonic acid into a reaction system, and stirring at room temperature for 3 hours; TLC monitoring reaction progress until reactant chlorogenic acid disappears; after the reaction is finished, adding a saturated sodium carbonate solution, neutralizing the residual p-toluenesulfonic acid until the pH value is 7, performing suction filtration, and concentrating the filtrate to obtain a compound A1;
step 2, protecting phenolic hydroxyl of chlorogenic acid: adding 9.2mmol of compound A1, 13.8mmol of acetic anhydride and 9.2mmol of DMAP into a 100mL round-bottom flask, dissolving with 30mL of DMF, and stirring at room temperature for reaction for 2 h; the reaction was monitored for completion, and the reaction was washed by addition of 20mL of saturated brine, extracted three times with dichloromethane (3X 10mL), and the organic phases were combined and purified by silica gel chromatography using dichloromethane and methanol as eluents at a dichloromethane to methanol volume ratio of 30: 1, isolating compound B1;
step 3, synthesis of chlorogenic acid derivatives containing oxazole ring: dissolving 8.6mmol of compound B1 in 20mL of DMF, adding 8.6mmol of nitrone dipole C1, 0.86mmol of copper acetate and 1.7mmol of m-CPBA into a reaction system, and reacting at 50 ℃ for 5 h; the reaction was stopped by TLC monitoring the progress of the reaction until compound B1 completely disappeared, 20mL of saturated brine was added to the reaction system, followed by three times of extraction with dichloromethane (3 × 10mL), and the organic phases were combined and purified by silica gel chromatography using dichloromethane and methanol as eluents at a dichloromethane to methanol volume ratio of 10: 1, isolating compound D1;
and 4, removing a hydroxyl protecting group: adding 7.6mmol of compound D1 into a mixture of 15.2mmol of trifluoroacetic acid and 7.6mmol of dichloromethane, reacting for 2h at room temperature, monitoring the reaction progress by TLC, washing twice with 20mL of saturated saline solution after the reaction is finished, extracting three times with dichloromethane (3X 10mL), combining organic phases, and purifying the organic phases by silica gel chromatography with dichloromethane and methanol as eluent and the volume ratio of dichloromethane to methanol being 20: 1, obtaining a compound E1, namely a chlorogenic acid derivative, with the yield of 80 percent and the nuclear magnetic hydrogen spectrum data as follows:
1HNMR(CDCl3,400MHz)：1.55-1.61(m,2H)，2.01(s,1H),2.06(s,1H),2.23-2.34(m,2H),3.31(s,3H),3.87(q,J＝8.0Hz,1H),4.03(m,1H),4.17(t,J＝6.5,1H),4.42(s,1H),5.0(s,1H),6.08(s,1H),6.79(s,1H),7.13(t,J＝6.0Hz,2H),7.28-7.36(m,2H),7.48-7.63(m,3H),8.13(s,1H),10.50(s,1H)。
step 5, determination of antibacterial Activity of Compound E1
Dissolving 1mmol of compound E1 in acetonitrile with different volumes respectively to prepare stock solutions with mass percentage concentrations of 20%, 40%, 60%, 80% and 100%; dipping with sterile cotton swab at 1.0 × 103cfu·m L-1Uniformly coating the bacterial liquid on the surface of a soybean casein agar culture medium plate, and sticking the bacterial liquid to the surface, wherein the strain used by the bacterial liquid is staphylococcus aureus; taking out the filter paper pieces soaked by the stock solutions with different concentrations by using a sterile forceps, throwing off the floating liquid on the surfaces of the filter paper pieces, and spreading the filter paper pieces on the surface of a soybean casein agar culture medium; placing the culture medium coated with the bacterial liquid into a culture dish, inverting the culture dish, placing the culture dish in a thermostat at 35 ℃ for culturing for 20 hours, and observing the phenomenon; the transparent circular ring-bacteriostasis ring appears on the culture medium, when the concentration ratio of the compound E1 is 60%, the bacteriostasis effect on staphylococcus aureus is obvious, the diameter of the bacteriostasis ring is 25.28mm, and the diameter of the bacteriostasis ring of chlorogenic acid under the same concentration is only 13.17 mm.
Example 2
A method for synthesizing chlorogenic acid derivatives comprises the following steps:
Figure BDA0002626550680000081
step 1, protecting alcoholic hydroxyl groups of chlorogenic acid: dissolving 10mmol of chlorogenic acid in 30mL of acetone, adding 11mmol of p-toluenesulfonic acid into a reaction system, and stirring at room temperature for 4 hours; TLC monitoring reaction progress until reactant chlorogenic acid disappears; after the reaction is finished, adding a saturated sodium carbonate solution, neutralizing the residual p-toluenesulfonic acid until the pH value is 7, performing suction filtration, and concentrating the filtrate to obtain a compound A2;
step 2, protecting phenolic hydroxyl of chlorogenic acid: adding 9.4mmol of compound A2, 18.8mmol of acetic anhydride and 10mmol of DMAP into a 100mL round-bottom flask, dissolving with 30mL of DMF, and stirring at room temperature for reaction for 2 h; the reaction was monitored for completion, and the reaction was washed by addition of 20mL of saturated brine, extracted three times with dichloromethane (3X 10mL), and the organic phases were combined and purified by silica gel chromatography using dichloromethane and methanol as eluents at a dichloromethane to methanol volume ratio of 30: 2, isolating compound B2;
step 3, synthesis of chlorogenic acid derivatives containing oxazole ring: dissolving 8.5mmol of compound B2 in 20mL of DMA, adding 10mmol of nitrone dipole C2, 0.85mmol of cupric bromide and 1.7mmol of m-CPBA into a reaction system, and reacting at the temperature of 60 ℃ for 7 h; the reaction was stopped by TLC monitoring the progress of the reaction until compound B2 completely disappeared, 20mL of saturated brine was added to the reaction system, followed by three times of extraction with dichloromethane (3 × 10mL), and the organic phases were combined and purified by silica gel chromatography using dichloromethane and methanol as eluents at a dichloromethane to methanol volume ratio of 10: 1.5, isolating compound D2;
and 4, removing a hydroxyl protecting group: adding 7.4mmol of compound D2 into a mixture of 17mmol of trifluoroacetic acid and 7.6mmol of dichloromethane, reacting at room temperature for 3h, monitoring the reaction progress by TLC, washing twice with 20mL of saturated saline solution after the reaction is finished, extracting five times with dichloromethane (5X 10mL), combining organic phases, and purifying the organic phases by silica gel chromatography with dichloromethane and methanol as eluent and the volume ratio of dichloromethane to methanol of 20: 1.5, compound E2, a chlorogenic acid derivative, was obtained in 82.5% yield with the following nuclear magnetic hydrogen spectroscopy data:
1HNMR(CDCl3,400MHz)：1.72-1.76(m,2H)，2.12(s,1H),2.26-2.34(m,2H),2.49(s,1H),3.00(s,1H),3.99(t,J＝8.5Hz,1H),4.05(q,J＝8.5Hz,1H),4.24(m,1H),4.60(s,1H),6.54(s,1H),6.89(s,1H),7.32-7.55(m,5H),7.61-7.78(m,4H),7.84-7.89(m,3H),8.70(s,1H),11.03(s,1H)。
step 5, determination of antibacterial Activity of Compound E2
Dissolving 2mmol of compound E2 in acetonitrile with different volumes respectively to prepare stock solutions with mass percentage concentrations of 20%, 40%, 60%, 80% and 100%; dipping with sterile cotton swab at 1.5X 103cfu·m L-1Uniformly coating the bacterial liquid on the surface of an eosin methylene blue agar culture medium plate, and sticking the bacterial liquid to the surface, wherein the strain used by the bacterial liquid is escherichia coli; taking out the filter paper pieces soaked by the stock solutions with different concentrations by using a sterile forceps, throwing off the floating liquid on the surfaces of the filter paper pieces, and spreading the filter paper pieces on the surface of an eosin methylene blue agar culture medium; placing the culture medium coated with the bacterial liquid into a culture dish, inverting the culture dish, placing the culture dish in a 37 ℃ incubator for culturing for 20 hours, and observing the phenomenon; the transparent circular ring-bacteriostasis zone appears on the culture medium, when the concentration ratio of the compound E2 is selected to be 40%, the bacteriostasis effect on escherichia coli is obvious, the diameter of the bacteriostasis zone is 27.33mm, and the diameter of the bacteriostasis zone of chlorogenic acid under the same concentration is 10.26 mm.
Example 3
A method for synthesizing chlorogenic acid derivatives comprises the following steps:
Figure BDA0002626550680000101
step 1, protecting alcoholic hydroxyl groups of chlorogenic acid: dissolving 10mmol of chlorogenic acid in 28mL of acetone, adding 11mmol of p-toluenesulfonic acid into a reaction system, and stirring at room temperature for 3.5 h; TLC monitoring reaction progress until reactant chlorogenic acid disappears; after the reaction is finished, adding a saturated sodium bicarbonate solution, neutralizing the residual p-toluenesulfonic acid until the pH value is 6.8, performing suction filtration, and concentrating the filtrate to obtain a compound A3;
step 2, protecting phenolic hydroxyl of chlorogenic acid: adding 9.4mmol of compound A3, 15.8mmol of acetic anhydride and 12mmol of DMAP into a 100mL round-bottom flask, dissolving with 32mL of DMF, and stirring at room temperature for reaction for 2.5 h; the reaction was monitored for completion, and the reaction was washed with 20mL of saturated brine, extracted four times with ethyl acetate (4X 10mL), and the organic phases were combined and purified by silica gel chromatography using dichloromethane and methanol as eluents at a dichloromethane to methanol volume ratio of 30: 2, isolating compound B3;
step 3, synthesis of chlorogenic acid derivatives containing oxazole ring: dissolving 8.9mmol of compound B3 in 25mL of 1,4-dioxane, adding 9.8mmol of nitrone dipole C3, 0.86mmol of copper trifluoromethanesulfonate and 2.7mmol of NBS into a reaction system, and reacting at 70 ℃ for 6 hours; the reaction was stopped by TLC monitoring the progress of the reaction until compound B3 completely disappeared, 20mL of saturated brine was added to the reaction system, followed by three times of extraction with ethyl acetate (3 × 10mL), and the organic phases were combined and purified by silica gel chromatography using dichloromethane and methanol as eluents at a dichloromethane to methanol volume ratio of 10: 2, isolating compound D3;
and 4, removing a hydroxyl protecting group: taking 7.7mmol of compound D3, adding a mixture of 19.2mmol of trifluoroacetic acid and 7.7mmol of dichloromethane, reacting at room temperature for 2.8h, monitoring the reaction progress by TLC, after the reaction is finished, washing twice by 20mL of saturated saline solution, extracting four times by ethyl acetate (4X 10mL), combining organic phases, and purifying the organic phases by silica gel chromatography with dichloromethane and methanol as eluent and the volume ratio of dichloromethane to methanol is 20: 1.5, compound E3, a chlorogenic acid derivative, was obtained in a yield of 75.9% with the following nuclear magnetic hydrogen spectroscopy data:
1HNMR(CDCl3,400MHz)：1.57-1.61(m,2H)，2.04(s,1H),2.33-2.38(m,2H),2.47(s,1H),3.83(t,J＝8.5Hz,1H),3.96(q,J＝8.5Hz,1H),4.26-4.29(m,1H),4.41(s,2H),4.57(t,J＝8.5Hz,1H),4.78(s,1H),5.45(s,1H),6.76(s,1H),7.10-7.26(m,6H),7.31-7.48(m,5H),7.50-7.52(m,1H),8.59(s,1H),10.16(s,1H)。
step 5, determination of antibacterial Activity of Compound E3
Dissolving 1mmol of compound E3 in acetonitrile with different volumes respectively to prepare stock solutions with mass percentage concentrations of 20%, 40%, 60%, 80% and 100%; dipping with sterile cotton swab at 1.3X 103cfu·m L-1Uniformly coating the bacterial liquid on the surface of a soybean casein agar culture medium plate, and sticking the bacterial liquid to the surface, wherein the strain used by the bacterial liquid is staphylococcus aureus; taking out the filter paper sheet soaked with the stock solutions with different concentrations by using sterile forceps, and throwingThe surface of the clean filter paper sheet is stained with floating liquid and is paved on the surface of a soybean casein agar culture medium; placing the culture medium coated with the bacterial liquid into a culture dish, inverting the culture dish, placing the culture dish in a 37 ℃ incubator for culturing for 22 hours, and observing the phenomenon; the transparent circular ring-bacteriostasis ring appears on the culture medium, when the concentration ratio of the compound E3 is selected to be 60%, the bacteriostasis effect on staphylococcus aureus is obvious, the diameter of the bacteriostasis ring is 24.11mm, and is 13.17mm higher than that of the bacteriostasis ring of chlorogenic acid under the same concentration.
Example 4
A method for synthesizing chlorogenic acid derivatives comprises the following steps:
Figure BDA0002626550680000121
step 1, protecting alcoholic hydroxyl groups of chlorogenic acid: dissolving 10mmol of chlorogenic acid in 30mL of acetone, adding 12mmol of p-toluenesulfonic acid into a reaction system, and stirring at room temperature for 4 hours; TLC monitoring reaction progress until reactant chlorogenic acid disappears; after the reaction is finished, adding a saturated sodium bicarbonate solution, neutralizing the residual p-toluenesulfonic acid until the pH value is 7.3, performing suction filtration, and concentrating the filtrate to obtain a compound A4;
step 2, protecting phenolic hydroxyl of chlorogenic acid: adding 9.5mmol of compound A4, 17.1mmol of acetic anhydride and 10.5mmol of DMAP into a 100mL round-bottom flask, dissolving with 25mL of DMF, and stirring at room temperature for reaction for 3 h; the reaction was monitored for completion, 20mL of saturated brine was added to the reaction system, the mixture was washed with n-butanol three times (3X 10mL), the organic phases were combined and purified by silica gel chromatography using dichloromethane and methanol as eluents at a dichloromethane to methanol volume ratio of 30: 2.5, isolating compound B4;
and 3, synthesizing a chlorogenic acid derivative containing a pyrazole ring: dissolving 8.9mmol of compound B4 in 25mL of DMSO, adding 10.7mmol of azomethine imine dipole C4, 0.89mmol of copper chloride and 3.6mmol of TBHP into a reaction system, and reacting at 60 ℃ for 6 h; the reaction was stopped by TLC monitoring the progress of the reaction until compound B4 completely disappeared, 20mL of saturated brine was added to the reaction system, followed by three times of n-butanol extraction (3 × 10mL), and the organic phases were combined and purified by silica gel chromatography using dichloromethane and methanol as eluents at a dichloromethane to methanol volume ratio of 10: 1.2, isolating compound D4;
and 4, removing a hydroxyl protecting group: taking 7.8mmol of compound D4, adding a mixture of 17.2mmol of trifluoroacetic acid and 7.8mmol of dichloromethane, reacting at room temperature for 2.5h, monitoring the reaction progress by TLC, washing three times with 20mL of saturated saline solution after the reaction is finished, extracting three times with n-butanol (3X 10mL), combining organic phases, and purifying the organic phases by silica gel chromatography with dichloromethane and methanol as eluent and the volume ratio of dichloromethane to methanol is 20: 1.8, Compound E4 was obtained in 83.2% yield with the following nuclear magnetic hydrogen spectroscopy data:
1HNMR(CDCl3,400MHz)：1.53-1.57(m,2H)，2.00(s,1H),2.09(s,3H),2.16-2.22(m,2H),2.19(t,J＝6.5Hz,2H),2.33(s,1H),3.10(s,1H),3.57(t,J＝6.5,2H),3.91(t,J＝8.5Hz,1H),4.16(q,t＝8.5Hz,1H),4.20(m,1H),4.48(s,1H),5.25(s,1H),6.81(s,1H),7.06-7.10(m,3H),7.26-7.36(m,3H),8.61(s,1H),10.27(s,1H)。
step 5, determination of antibacterial Activity of Compound E4
Dissolving 1mmol of compound E4 in acetonitrile with different volumes respectively to prepare stock solutions with mass percentage concentrations of 20%, 40%, 60%, 80% and 100%; dipping with sterile cotton swab at 1.8 × 103cfu·m L-1Uniformly coating the bacterial liquid on the surface of a soybean casein agar culture medium plate, and sticking the bacterial liquid to the surface, wherein the strain used by the bacterial liquid is staphylococcus aureus; taking out the filter paper pieces soaked by the stock solutions with different concentrations by using a sterile forceps, throwing off the floating liquid on the surfaces of the filter paper pieces, and spreading the filter paper pieces on the surface of a soybean casein agar culture medium; placing the culture medium coated with the bacterial liquid into a culture dish, inverting the culture dish, placing the culture dish in a thermostat at 36 ℃ for culturing for 24 hours, and observing the phenomenon; the transparent circular ring-bacteriostasis circle appears on the culture medium, when the concentration ratio of the compound E4 is selected to be 60%, the bacteriostasis effect on staphylococcus aureus is obvious, the diameter of the bacteriostasis circle is 28.04mm, which is far higher than the diameter of the bacteriostasis circle of chlorogenic acid under the same concentration, which is 13.17 mm.
Example 5
A method for synthesizing chlorogenic acid derivatives comprises the following steps:
Figure BDA0002626550680000141
step 1, protecting alcoholic hydroxyl groups of chlorogenic acid: dissolving 10mmol of chlorogenic acid in 24mL of acetone, adding 12mmol of p-toluenesulfonic acid into a reaction system, and stirring at room temperature for 4.5 h; TLC monitoring reaction progress until reactant chlorogenic acid disappears; after the reaction is finished, adding a saturated sodium bicarbonate solution, neutralizing the residual p-toluenesulfonic acid until the pH value is 7, carrying out suction filtration, and concentrating the filtrate to obtain a compound A5;
step 2, protecting phenolic hydroxyl of chlorogenic acid: adding 9.3mmol of compound A5, 14.9mmol of acetic anhydride and 11.2mmol of DMAP into a 100mL round-bottom flask, dissolving with 27mL of DMF, and stirring at room temperature for reaction for 3 h; the reaction was monitored for completion, and the reaction was washed by addition of 20mL of saturated brine, extracted three times with dichloromethane (3X 10mL), and the organic phases were combined and purified by silica gel chromatography using dichloromethane and methanol as eluents at a dichloromethane to methanol volume ratio of 30: 3, isolating compound B5;
and 3, synthesizing a chlorogenic acid derivative containing a pyrazole ring: dissolving 8.9mmol of compound B5 in 30mL of acetonitrile, adding 9.8mmol of azomethine imine dipole C5, 1.3mmol of cuprous acetate and 4.5mmol of iodobenzene acetate into a reaction system, and reacting at 60 ℃ for 8 h; the reaction was stopped by TLC monitoring the progress of the reaction until compound B5 completely disappeared, 20mL of saturated brine was added to the reaction system, followed by three times of extraction with dichloromethane (3 × 10mL), and the organic phases were combined and purified by silica gel chromatography using dichloromethane and methanol as eluents at a dichloromethane to methanol volume ratio of 10: 1.6, compound D5 is isolated;
and 4, removing a hydroxyl protecting group: adding 7.7mmol of compound D5 into a mixture of 16.2mmol of trifluoroacetic acid and 7.7mmol of dichloromethane, reacting at room temperature for 3h, monitoring the reaction progress by TLC, washing twice with 20mL of saturated saline solution after the reaction is finished, extracting three times with dichloromethane (3X 10mL), combining organic phases, and purifying the organic phases by silica gel chromatography with dichloromethane and methanol as eluent and the volume ratio of dichloromethane to methanol of 20: 1.4, Compound E5 was obtained in 84.3% yield with the following nuclear magnetic hydrogen spectroscopy data:
1HNMR(CDCl3,400MHz)：1.81-1.84(m,2H)，2.07(s,1H),2.47-2.49(m,2H),2.23(t,J＝6.5Hz,2H),2.31(s,1H),2.64(s,1H),3.63(t,J＝6.5Hz,2H),3.79(s,1H),4.03(t,J＝8.5Hz,1H),4.16(q,t＝8.5Hz,1H),4.22(m,1H),5.61(s,1H),6.95(s,1H),7.16-7.22(m,3H),7.28-7.35(m,2H),7.43(m,1H),8.25(s,1H),11.13(s,1H)。
step 5, determination of antibacterial Activity of Compound E5
Dissolving 1.5mmol of compound E5 in acetonitrile with different volumes respectively to prepare stock solutions with mass percentage concentrations of 20%, 40%, 60%, 80% and 100%; dipping with sterile cotton swab at 1.6X 103cfu·m L-1Uniformly coating the bacterial liquid on the surface of an eosin methylene blue agar culture medium plate, and sticking the bacterial liquid to the surface, wherein the strain used by the bacterial liquid is candida albicans; taking out the filter paper pieces soaked by the stock solutions with different concentrations by using a sterile forceps, throwing off the floating liquid on the surfaces of the filter paper pieces, and spreading the filter paper pieces on the surface of an eosin methylene blue agar culture medium; placing the culture medium coated with the bacterial liquid into a culture dish, inverting the culture dish, placing the culture dish in a thermostat at 36 ℃ for culturing for 24 hours, and observing the phenomenon; the culture medium is found to have a transparent circular ring-bacteriostasis zone, when the concentration ratio of the compound E5 is 80%, the bacteriostasis effect on the candida albicans is remarkable, the diameter of the bacteriostasis zone is 26.32mm, which is far higher than that of the bacteriostasis zone of chlorogenic acid under the same concentration, and is 9.98 mm.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included within the scope of the present invention.

Claims (10)

1. A method for synthesizing chlorogenic acid derivatives is characterized by comprising the following steps: which comprises the following steps:
step 1, protecting alcoholic hydroxyl groups of chlorogenic acid: dissolving chlorogenic acid in acetone, adding p-toluenesulfonic acid into a reaction system, and stirring at room temperature for 3-5 hours; TLC monitoring reaction progress until reactant chlorogenic acid disappears; after the reaction is finished, adding an alkaline substance, neutralizing the residual p-toluenesulfonic acid until the pH value is 6-7.5, performing suction filtration, and concentrating the filtrate to obtain a compound A;
step 2, protecting phenolic hydroxyl of chlorogenic acid: adding the compound A obtained in the step 1, acetic anhydride with a phenolic hydroxyl protecting group and a catalyst 4-dimethylaminopyridine into a solvent dimethylformamide, and stirring and reacting for 2-3 h at room temperature; monitoring the reaction, adding saturated saline solution into the reaction system for washing, then extracting by using an extracting agent, combining organic phases, purifying the organic phases by using silica gel chromatography, and separating out a compound B by using dichloromethane and methanol as eluent;
and 3, synthesizing chlorogenic acid derivatives containing oxazole or pyrazole rings: dissolving the compound B obtained in the step 2 in an organic solvent, adding 1, 3-dipole C, a catalyst copper salt and an oxidant into a reaction system, and reacting at the temperature of 50-70 ℃ for 5-8 h; TLC monitoring reaction progress until compound B disappears completely, stopping reaction, adding saturated salt solution into reaction system, washing, extracting with extractant, combining organic phase, purifying organic phase with silica gel chromatography, eluting with dichloromethane and methanol to separate out compound D;
the 1, 3-dipole C is of the formula (I)
Figure FDA0002626550670000011
Wherein R is H, Bn, Me, Ph, 4-MePh, 4-MeOPh, 4-ClPh or CH2CH2CO; ar is Ph, 4-MePh, 4-MeOPh, 4-ClPh, 2-MePh or 2-ClPh; x is O or N;
and 4, removing a hydroxyl protecting group: adding the compound D obtained in the step 3 into a mixture of trifluoroacetic acid and dichloromethane, reacting at room temperature for 1.5-3 h, monitoring the reaction process by TLC, after the reaction is finished, adding saturated salt solution into a reaction system for washing, extracting with an extracting agent, combining organic phases, purifying the organic phases by silica gel chromatography, and taking dichloromethane and methanol as eluents to obtain a final product E, namely a chlorogenic acid derivative, wherein the yield is 70-85%;
the synthetic route is as follows:
Figure FDA0002626550670000021
2. the method for synthesizing a chlorogenic acid derivative as claimed in claim 1, wherein: in the step 1, the dosage ratio of chlorogenic acid to acetone is 10 mmol: 20-30 mL, wherein the molar ratio of chlorogenic acid to p-toluenesulfonic acid is 1: 1.0-1.2, and the alkaline substance is saturated sodium carbonate or saturated sodium bicarbonate.
3. The method for synthesizing a chlorogenic acid derivative as claimed in claim 1, wherein: in the step 2, the molar ratio of the compound A, acetic anhydride and 4-dimethylamino pyridine is 1: 1.5-2.0: 1-1.5, wherein the dosage ratio of the compound A to the dimethylformamide is 10 mmol: 25-35 mL, wherein the volume ratio of dichloromethane to methanol is 30: 1 to 3.
4. The method for synthesizing a chlorogenic acid derivative as claimed in claim 1, wherein: in the step 3, the dosage ratio of the compound B to the organic solvent is 10 mmol: 20-30 mL, wherein the molar ratio of the compound B to the 1, 3-dipole C to the catalyst copper salt to the oxidant is 1: 1.0-1.2: 0.1-0.2: 0.2-0.5, wherein the volume ratio of dichloromethane to methanol is 10: 1 to 2.
5. The method for synthesizing a chlorogenic acid derivative according to claim 1 or 4, characterized in that: in the step 3, the copper salt of the catalyst is cupric chloride, cupric bromide, cupric acetate, cuprous acetate, cupric trifluoroacetate or cupric trifluoromethanesulfonate.
6. The method for synthesizing a chlorogenic acid derivative according to claim 1 or 4, characterized in that: in the step 3, the oxidant is tert-butyl alcohol peroxide, m-chloroperoxybenzoic acid, N-bromosuccinimide, 2,6, 6-tetramethyl piperidinyloxy ammonium tetrafluoroborate or iodobenzene acetate; the organic solvent is DMF, DMA, DMSO, 1,4-dioxane, 1,2-dichloroethane、CH3CN or THF.
7. The method for synthesizing a chlorogenic acid derivative as claimed in claim 1, wherein: in the step 4, the molar ratio of the compound D, trifluoroacetic acid and dichloromethane is 1: 2-3: 1, the volume ratio of dichloromethane to methanol is 20: 1 to 2.
8. A method for the synthesis of a chlorogenic acid derivative according to any of claims 1 to 7, characterized by: the structural formula of the chlorogenic acid derivative prepared by the method is shown as formula (II):
Figure FDA0002626550670000031
wherein R is H, Bn, Me, Ph, 4-MePh, 4-MeOPh, 4-ClPh or CH2CH2CO; ar is Ph, 4-MePh, 4-MeOPh, 4-ClPh, 2-MePh or 2-ClPh; x is O or N.
9. A method for measuring antibacterial activity of chlorogenic acid derivative prepared by the synthesis method of claim 8, which comprises the following steps: which comprises the following steps: dissolving chlorogenic acid derivatives with acetonitrile as solvent, and preparing into stock solutions with mass percentage concentrations of 20%, 40%, 60%, 80%, and 100%, respectively; dipping with sterile cotton swab at 1.0 × 103～2.0×103cfu·mL-1The bacterial liquid is uniformly coated on the surface of a culture medium plate and is pasted firmly, and the used strain of the bacterial liquid is escherichia coli, staphylococcus aureus or candida albicans; taking out the filter paper sheets soaked by the stock solutions with different concentrations by using sterile forceps, and spreading the filter paper sheets on the surfaces of different culture media; putting the culture medium coated with the bacterial liquid into a culture dish, inverting the culture dish, putting the culture dish into a thermostat with the temperature of 35-37 ℃ for culturing for 20-24 hours, and observing the phenomenon; transparent circular rings-bacteriostatic rings with different sizes appear on the culture medium respectively, and the bacteriostatic activity of the chlorogenic acid derivative can be obtained by measuring the diameters of the bacteriostatic rings.
10. Use of chlorogenic acid derivative prepared by the synthesis method of claim 8 in preparing antibacterial drugs.
CN202010798623.3A 2020-08-11 2020-08-11 Synthesis method of chlorogenic acid derivative and antibacterial activity determination method Active CN111848537B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010798623.3A CN111848537B (en) 2020-08-11 2020-08-11 Synthesis method of chlorogenic acid derivative and antibacterial activity determination method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010798623.3A CN111848537B (en) 2020-08-11 2020-08-11 Synthesis method of chlorogenic acid derivative and antibacterial activity determination method

Publications (2)

Publication Number Publication Date
CN111848537A true CN111848537A (en) 2020-10-30
CN111848537B CN111848537B (en) 2022-10-28

Family

ID=72972468

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010798623.3A Active CN111848537B (en) 2020-08-11 2020-08-11 Synthesis method of chlorogenic acid derivative and antibacterial activity determination method

Country Status (1)

Country Link
CN (1) CN111848537B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114773255A (en) * 2022-05-24 2022-07-22 遵义医科大学 Chlorogenic acid analogue and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101120937A (en) * 2006-08-11 2008-02-13 四川九章生物化工科技发展有限公司 Application of chlorogenic acid in preparing medicine with cervical cancer preventing and treating efficiency
CN101293832A (en) * 2008-06-12 2008-10-29 浙江大学 Process for synthesizing chlorogenic acid and its derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101120937A (en) * 2006-08-11 2008-02-13 四川九章生物化工科技发展有限公司 Application of chlorogenic acid in preparing medicine with cervical cancer preventing and treating efficiency
CN101293832A (en) * 2008-06-12 2008-10-29 浙江大学 Process for synthesizing chlorogenic acid and its derivative

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114773255A (en) * 2022-05-24 2022-07-22 遵义医科大学 Chlorogenic acid analogue and preparation method and application thereof

Also Published As

Publication number Publication date
CN111848537B (en) 2022-10-28

Similar Documents

Publication Publication Date Title
FR2745290A1 (en) NOVEL DERIVATIVES OF ERYTHROMYCIN, PROCESS FOR PREPARING THEM AND THEIR APPLICATION AS MEDICAMENTS
WO2007082475A1 (en) Novel ent-kaurene diterpene compound and its derivatives, their preparation and their use
CN101665491B (en) Synthetic method of berberine 13-bit derivant and berberrubine 13-bit derivant
CN111848537B (en) Synthesis method of chlorogenic acid derivative and antibacterial activity determination method
CN104974123B (en) Coumarin kind compound with antioxidation activity and preparation method and application
CN106188212A (en) The application in antibacterials of Cleistanone derivant and pharmaceutically acceptable salt
CN105646392B (en) 1,3,4 oxadiazole class compounds, its preparation method and the application of the fat of oxime containing carboxylic acid
CN107286220B (en) 1,2, 4-triazole coupled dihydromyricetin derivative and preparation method and application thereof
EP1173455A2 (en) Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments
CN101671376B (en) Alkannin acetyl glucose and preparation method and application thereof
CN111303027A (en) Fluroxacin acrylketone derivative and preparation method and application thereof
CN104188984B (en) The application in preparation antibacterials of O-(morpholinyl) ethyl derivative of Cleistanone Cleistanone
CN112824391A (en) Propylene ketone derivative of gatifloxacin and preparation method and application thereof
CN102690332B (en) Antimicrobial-oritavancin derivative and pharmaceutical composition, with and its production and use
CN112321580B (en) Oxazole linked triazole medicine molecule for sterilization and disinfection and preparation method and application thereof
WO2004101543A1 (en) Coumarins compounds, the preparation and the use thereof
CN110669100B (en) Metronidazole serine-asparagine dipeptide compound and preparation and application thereof
CN108623644B (en) Paulomycin derivatives and preparation method and application thereof
CN106518648B (en) A kind of synthetic method of 2- hydroxyl chinic acid
CN107325030A (en) The new trans-stilbene class antitumor agent of one class
CN114097804A (en) Application of diaminopyrimidine compound in preventing and treating agricultural pathogenic bacteria
CN107652262B (en) Preparation method and application of amicumacecin isocoumarin compound
JP2512050B2 (en) Novel antifungal antibiotic dexylosylvenanomycin B and method for producing the same
CN106188019B (en) The Preparation method and use of a kind of baicalein -7- methyl ether derivative
CN104523706B (en) The application in preparation antibacterials of O-(imidazole radicals) ethyl derivative of Cleistanone Cleistanone

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant